Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flurbiprofen axetil + ropivacaine
- Development stage
- Unknown
- Lead developer
- Beijing Tiantan Hospital
- Modality
- Small Molecules
- Administration
- Local Infiltration
01
Overview
This is an investigational combination therapy consisting of flurbiprofen axetil and ropivacaine, being evaluated for the management of postoperative pain following craniotomy. Flurbiprofen axetil is a non-steroidal anti-inflammatory drug (NSAID) prodrug formulated in emulsified lipid microspheres, which is hydrolyzed by esterases to its active form, flurbiprofen. It acts by inhibiting cyclooxygenase enzymes, thereby reducing prostaglandin synthesis at the site of injury. Ropivacaine is a long-acting amide-type local anesthetic that blocks voltage-gated sodium channels, preventing the conduction of nerve impulses. The combination is administered via pre-emptive scalp infiltration to provide superior analgesia and reduce the requirement for postoperative opioids. This specific regimen is being studied in a multicenter randomized controlled trial led by Beijing Tiantan Hospital.
- Other names
- FA + Ropivacaineflurbiprofen axetil and ropivacaine
02
Targets
NaV (Voltage-gated sodium channels)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on flurbiprofen axetil + ropivacaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flurbiprofen axetil + ropivacaine.